Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Provided By GlobeNewswire
Last update: Mar 31, 2025
TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose
New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time
Read more at globenewswire.com
